A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects
about
A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
A Novel NF-κB Inhibitor, Edasa ...... macodynamics in Adult Subjects
@ast
A Novel NF-κB Inhibitor, Edasa ...... macodynamics in Adult Subjects
@en
type
label
A Novel NF-κB Inhibitor, Edasa ...... macodynamics in Adult Subjects
@ast
A Novel NF-κB Inhibitor, Edasa ...... macodynamics in Adult Subjects
@en
prefLabel
A Novel NF-κB Inhibitor, Edasa ...... macodynamics in Adult Subjects
@ast
A Novel NF-κB Inhibitor, Edasa ...... macodynamics in Adult Subjects
@en
P2093
P2860
P356
P1476
A Novel NF-κB Inhibitor, Edasa ...... macodynamics in Adult Subjects
@en
P2093
Elliot Offman
Joanne M Donovan
Michael Jirousek
Michael Zimmer
Toni Grant
P2860
P304
P356
10.1002/JCPH.842
P577
2017-01-11T00:00:00Z